Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription Articles published in J Infect Retrieve available abstracts of 76 articles: HTML format

Single Articles

June 2025
1. BERTRAN M, Abdullahi F, D'Aeth JC, Amin-Chowdhury Z, et al
   Recurrent invasive pneumococcal disease in children: A retrospective cohort study, England, 2006/07-2017/18.
   J Infect. 2025;90:106490.
   PubMed     Abstract available
   
   
   May 2025
2. OLIVEIRA LVN, Hargarten JC, Wang R, Carlson D, et al
   Peripheral blood CD4(+) and CD8(+) T cell responses to Cryptococcus candidate vaccine antigens in human subjects with and without cryptococcosis.
   J Infect. 2025;91:106521.
   PubMed     Abstract available
   
   
   
3. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
   Corrigendum to "Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: A cohort study" [J Infect 90 (2025) 106497].
   J Infect. 2025;91:106522.
   PubMed    
   
   
   
4. CHACON GP, McAlister S, Totterdell J, Estcourt MJ, et al
   Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines.
   J Infect. 2025 May 23:106515. doi: 10.1016/j.jinf.2025.106515.
   PubMed     Abstract available
   
   
   April 2025
5. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
   Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
   J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
   PubMed     Abstract available
   
   
   
6. SEPPANEN EJ, Bayliss J, Clark SL, Gamez C, et al
   Haemophilus influenzae remains the predominant otitis media pathogen in Australian children undergoing ventilation tube insertion in the PCV13 era.
   J Infect. 2025;90:106478.
   PubMed     Abstract available
   
   
   March 2025
7. PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al
   Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
   J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473.
   PubMed     Abstract available
   
   
   
8. WARD T, Paton RS, Overton CE, Mellor J, et al
   Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey.
   J Infect. 2025 Mar 5:106461. doi: 10.1016/j.jinf.2025.106461.
   PubMed     Abstract available
   
   
   February 2025
9. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
   The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose.
   J Infect. 2025 Feb 18:106447. doi: 10.1016/j.jinf.2025.106447.
   PubMed     Abstract available
   
   
   
10. WILLIAMS KV, Krauland MG, Nowalk MP, Harrison LH, et al
    Increasing child vaccination coverage can reduce influenza cases across age groups: An agent-based modeling study.
    J Infect. 2025;90:106443.
    PubMed     Abstract available
    
    
    
11. NOBLE C, McDonald E, Nicholson S, Biering-Sorensen S, et al
    Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.
    J Infect. 2025 Feb 6:106436. doi: 10.1016/j.jinf.2025.106436.
    PubMed     Abstract available
    
    
    
12. ZIMAKOFF AC, Jensen A, Malon M, Sorensen JK, et al
    Measles-mumps-rubella vaccination at 6 months of age and the risk of atopic disease in the first year of life: Results from a Danish placebo-controlled randomised trial.
    J Infect. 2025 Feb 2:106433. doi: 10.1016/j.jinf.2025.106433.
    PubMed     Abstract available
    
    
    January 2025
13. BENNETT C, Chau G, Clayton E, Chu L, et al
    Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial.
    J Infect. 2025 Jan 26:106428. doi: 10.1016/j.jinf.2025.106428.
    PubMed     Abstract available
    
    
    
14. YANG Y, Knoll MD, Herbert C, Bennett JC, et al
    Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: the PSERENADE project.
    J Infect. 2025 Jan 24:106426. doi: 10.1016/j.jinf.2025.106426.
    PubMed     Abstract available
    
    
    
15. SILVA SOUZA M, Pires Farias J, de Souza Ferreira LC, Amorim JH, et al
    Declining COVID-19 vaccination coverage in Brazil: A global health warning.
    J Infect. 2025;90:106418.
    PubMed    
    
    
    
16. ZHANG S, Liu J
    Optimization of Diphtheria, Tetanus and Pertussis (DTP) vaccination strategy in China.
    J Infect. 2025;90:106416.
    PubMed    
    
    
    
17. FENG S, Bibi S, Aley PK, Cappuccini F, et al
    Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
    J Infect. 2025;90:106423.
    PubMed     Abstract available
    
    
    
18. RJOOB K, Antonelli M, Murray B, Molteni E, et al
    Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post COVID-19 Syndrome After SARS-CoV-2 Vaccination Versus Influenza Vaccination.
    J Infect. 2025 Jan 10:106406. doi: 10.1016/j.jinf.2024.106406.
    PubMed     Abstract available
    
    
    
19. GEHRT L, Moller S, Englund H, Laake I, et al
    Vaccination against measles-mumps-rubella and rates of non-targeted infectious disease hospitalisations: Nationwide register-based cohort studies in Denmark, Finland, Norway, and Sweden.
    J Infect. 2025 Jan 7:106365. doi: 10.1016/j.jinf.2024.106365.
    PubMed     Abstract available
    
    
    
20. ONG DS, Harris M, Hart JD, Russell FM, et al
    Lack of correlation between school reopening and trends in adult COVID-19 hospitalisations and death rates during the Delta and early Omicron periods: an ecological analysis of five countries.
    J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390.
    PubMed     Abstract available
    
    
    
21. JORDA A, Prager M, Pracher L, Haselwanter P, et al
    Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised, Double-blind, Placebo-contro
    J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405.
    PubMed     Abstract available
    
    
    December 2024
22. YANG Y, Shen X, Hu H, Wang Y, et al
    The need for inclusion of the Hib vaccine in mainland national immunization program in China.
    J Infect. 2024 Dec 23:106386. doi: 10.1016/j.jinf.2024.106386.
    PubMed    
    
    
    
23. MOK CKP, Tang YS, Tan CW, Chong KC, et al
    Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
    J Infect. 2024;90:106374.
    PubMed     Abstract available
    
    
    
24. BORROW R, Campbell H, Caugant DA, Cherkaoui A, et al
    Global Meningococcal Initiative: Insights on antibiotic resistance, control strategies and advocacy efforts in Western Europe.
    J Infect. 2024;89:106335.
    PubMed     Abstract available
    
    
    November 2024
25. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed     Abstract available
    
    
    
26. CHOW KN, Tsang YW, Chan YH, Telaga SA, et al
    The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis.
    J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358.
    PubMed     Abstract available
    
    
    
27. MCLEOD C, Dymock M, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
    J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346.
    PubMed     Abstract available
    
    
    
28. MAHTAB S, Madewell ZJ, Baillie V, Dangor Z, et al
    Etiologies and Comorbidities of Meningitis Deaths in Children Under 5 Years in High-Mortality Settings: Insights from the CHAMPS Network in the Post-Pneumococcal Vaccine Era.
    J Infect. 2024 Nov 7:106341. doi: 10.1016/j.jinf.2024.106341.
    PubMed     Abstract available
    
    
    
29. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed     Abstract available
    
    
    
30. LIU Y, Yu D, Wang K, Ye Q, et al
    Global resurgence of pertussis: A perspective from China.
    J Infect. 2024;89:106289.
    PubMed     Abstract available
    
    
    October 2024
31. WANG H, Zhou Y, Chu L, Chen K, et al
    Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
    J Infect. 2024;89:106333.
    PubMed    
    
    
    
32. CHEN X, Meng X, Wu Q, Lim WW, et al
    Assessment of Neutralizing Antibody Response as a Correlate of Protection against Symptomatic SARS-CoV-2 Infections after Administration of two doses of the CoronaVac inactivated COVID-19 Vaccine: A Phase III Randomized Controlled Trial.
    J Infect. 2024 Oct 16:106315. doi: 10.1016/j.jinf.2024.106315.
    PubMed     Abstract available
    
    
    
33. MADSEN AMR, Gehrt L, Schaltz-Buchholzer F, Moller S, et al
    Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: a randomised clinical trial.
    J Infect. 2024 Oct 16:106319. doi: 10.1016/j.jinf.2024.106319.
    PubMed     Abstract available
    
    
    
34. MARCHESE AM, Fries L, Beyhaghi H, Vadivale M, et al
    Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines.
    J Infect. 2024 Oct 15:106317. doi: 10.1016/j.jinf.2024.106317.
    PubMed     Abstract available
    
    
    
35. MATUSALI G, Cimini E, Mazzotta V, Colavita F, et al
    Mpox Immune response elicited by MVA-BN vaccine over 12 months of follow-up.
    J Infect. 2024;89:106309.
    PubMed    
    
    
    
36. HANI E, Abdullahi F, Bertran M, Eletu S, et al
    Trends in invasive Haemophilus influenzae serotype b (Hib) disease in England: 2012/13 to 2022/23.
    J Infect. 2024;89:106247.
    PubMed     Abstract available
    
    
    September 2024
37. NANQUE LM, Varma A, Thysen SM, Benn CS, et al
    Effect of a campaign with oral polio vaccine on general health: A cluster-randomised trial in rural Guinea-Bissau.
    J Infect. 2024 Sep 30:106302. doi: 10.1016/j.jinf.2024.106302.
    PubMed     Abstract available
    
    
    
38. BENNETT C, Hoosain Z, Koen A, Lalloo U, et al
    Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial.
    J Infect. 2024 Sep 27:106285. doi: 10.1016/j.jinf.2024.106285.
    PubMed     Abstract available
    
    
    
39. KIRWAN PD, Foulkes S, Munro K, Sparkes D, et al
    Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024.
    J Infect. 2024 Sep 27:106293. doi: 10.1016/j.jinf.2024.106293.
    PubMed     Abstract available
    
    
    
40. RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al
    N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.
    J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288.
    PubMed     Abstract available
    
    
    
41. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    PubMed     Abstract available
    
    
    
42. FAUSTINI SE, Hodson J, Birtwistle J, Whitelegg A, et al
    Comparison of short- and long-term humoral immune responses to pneumococcal polysaccharide and glycoconjugate vaccines in an HIV-infected population.
    J Infect. 2024 Sep 24:106282. doi: 10.1016/j.jinf.2024.106282.
    PubMed     Abstract available
    
    
    
43. CHRISTENSEN J, Johansen ND, Janstrup KH, Modin D, et al
    Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the DANFLU-1 randomized clinical trial.
    J Infect. 2024 Sep 18:106276. doi: 10.1016/j.jinf.2024.106276.
    PubMed     Abstract available
    
    
    
44. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    Corrigendum to "The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials" [J Infect 89 (2024) 106187].
    J Infect. 2024;89:106270.
    PubMed    
    
    
    August 2024
45. AZIZ AB, Sugimoto JD, Hong SL, You YA, et al
    Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: a cluster randomised analysis.
    J Infect. 2024 Aug 30:106260. doi: 10.1016/j.jinf.2024.106260.
    PubMed     Abstract available
    
    
    
46. GRAM MA, Thiesson EM, Pihlstrom N, Perala J, et al
    Comparative effectiveness of bivalent BA.4-5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study.
    J Infect. 2024;89:106261.
    PubMed     Abstract available
    
    
    
47. FOULKES S, Evans J, Neill C, Bishop J, et al
    Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among healthcare workers: a cross-sectional survey in the SIREN cohort.
    J Infect. 2024 Aug 28:106259. doi: 10.1016/j.jinf.2024.106259.
    PubMed     Abstract available
    
    
    
48. FRYER HA, Geers D, Gommers L, Zaeck LM, et al
    Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    J Infect. 2024 Aug 8:106246. doi: 10.1016/j.jinf.2024.106246.
    PubMed     Abstract available
    
    
    
49. MESSINA NL, Pittet LF, McDonald E, Moore C, et al
    BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial.
    J Infect. 2024 Aug 8:106245. doi: 10.1016/j.jinf.2024.106245.
    PubMed     Abstract available
    
    
    
50. FAN C, Yang Y, Zhan S, Sun X, et al
    The effectiveness and impact of the enterovirus 71 vaccine on the onset of hand, foot, and mouth disease in children aged
    J Infect. 2024;89:106244.
    PubMed    
    
    
    
51. ALABI A, Kokou K, Mahmoudou S, Kavishna R, et al
    Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-DeltaG-ZEBOV-GP in a sub-Saharan African paediatric population: a randomised controlled, open-label trial in children aged 1-12 years living in Lambarene, Gabon.
    J Infect. 2024 Aug 7:106237. doi: 10.1016/j.jinf.2024.106237.
    PubMed     Abstract available
    
    
    
52. QUEK AML, Wang S, Teng O, Shunmuganathan B, et al
    Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals.
    J Infect. 2024 Aug 7:106238. doi: 10.1016/j.jinf.2024.106238.
    PubMed     Abstract available
    
    
    
53. SILVA-COSTA C, Gomes-Silva J, Pinho M, Friaes A, et al
    Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19 pandemic was not associated with significant serotype changes.
    J Infect. 2024 Aug 6:106242. doi: 10.1016/j.jinf.2024.106242.
    PubMed     Abstract available
    
    
    July 2024
54. ANDREWS N, Osuntoki I, Stowe J, Kirsebom FCM, et al
    The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in England 2022/23.
    J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221.
    PubMed     Abstract available
    
    
    
55. GRISKAITIS M, Thielemann I, Schonfeld V, Falman A, et al
    Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.
    J Infect. 2024;89:106228.
    PubMed     Abstract available
    
    
    
56. WANG B, Mohammed H, Andraweera P, McMillan M, et al
    Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.
    J Infect. 2024 Jul 8:106225. doi: 10.1016/j.jinf.2024.106225.
    PubMed     Abstract available
    
    
    June 2024
57. DU Z, Wang S, Chen R, Shan S, et al
    Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults.
    J Infect. 2024;89:106211.
    PubMed    
    
    
    
58. GONG X, Peng L, Wang F, Liu J, et al
    Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    J Infect. 2024;89:106208.
    PubMed     Abstract available
    
    
    
59. PEREZ-GARCIA C, Sempere J, de Miguel S, Hita S, et al
    Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023).
    J Infect. 2024;89:106204.
    PubMed     Abstract available
    
    
    
60. ZHAI K, Dong J, Zeng J, Cheng P, et al
    Global Antigenic Landscape and Vaccine Recommendation Strategy for Low Pathogenic Avian Influenza A(H9N2) Viruses.
    J Infect. 2024 Jun 18:106199. doi: 10.1016/j.jinf.2024.106199.
    PubMed     Abstract available
    
    
    
61. AUDRAN R, Karoui O, Donnet L, Soumas V, et al
    Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
    J Infect. 2024 Jun 17:106205. doi: 10.1016/j.jinf.2024.106205.
    PubMed     Abstract available
    
    
    
62. MIKOLAJCZYK R, Diexer S, Klee B, Pfrommer L, et al
    Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
    J Infect. 2024 Jun 17:106206. doi: 10.1016/j.jinf.2024.106206.
    PubMed     Abstract available
    
    
    
63. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron.
    J Infect. 2024;88:106165.
    PubMed    
    
    
    
64. TSANG RSW, Deceuninck G, Meilleur C, Zhou J, et al
    Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex.
    J Infect. 2024;88:106163.
    PubMed     Abstract available
    
    
    May 2024
65. SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al
    The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
    J Infect. 2024;89:106187.
    PubMed     Abstract available
    
    
    
66. AMANO M, Ichikawa Y, Matsumoto S, Higashi-Kuwata N, et al
    Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination.
    J Infect. 2024;89:106179.
    PubMed    
    
    
    
67. PANG CWK, Vale R, Lao KS, Khan AT, et al
    Increased Incidence of Invasive Pneumococcal Disease in Hong Kong in 2023.
    J Infect. 2024 May 11:106178. doi: 10.1016/j.jinf.2024.106178.
    PubMed     Abstract available
    
    
    
68. KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al
    Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177.
    PubMed     Abstract available
    
    
    April 2024
69. MENGYANG G, Yahong H, Qinghong M, Wei S, et al
    Resurgence and atypical patterns of pertussis in China.
    J Infect. 2024;88:106140.
    PubMed    
    
    
    March 2024
70. NG M, S D, L W, R B, et al
    Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology.
    J Infect. 2024 Mar 27:106145. doi: 10.1016/j.jinf.2024.106145.
    PubMed     Abstract available
    
    
    
71. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
    PubMed    
    
    
    
72. SUN L, Man Q, Zhang H, Xia S, et al
    Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination.
    J Infect. 2024;88:106138.
    PubMed    
    
    
    
73. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    PubMed     Abstract available
    
    
    
74. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    PubMed     Abstract available
    
    
    February 2024
75. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
    AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
    J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
    PubMed     Abstract available
    
    
    September 2023
76. CLARK SA, Campbell H, Ribeiro S, Bertran M, et al
    Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England.
    J Infect. 2023 Sep 7:S0163-4453(23)00504-2. doi: 10.1016/j.jinf.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.